NCT00312416

Effects of Topical Clonidine vs. Brimonidine on Choroidal Blood Flow and Intraocular Pressure During Isometric Exercise

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 18 (planned)
• Sponsor: Medical University of Vienna · Academic / Other
• Sex: Male
• Age: 19 Years – 35 Years
• Healthy volunteers: Accepted

Summary

Brimonidine tartrate is an alpha-2 agonist ocular hypotensive drug that exerts its effect by causing both a decrease in aqueous production and an increase in uveoscleral outflow. It has been proven to reduce increased intraocular pressure in glaucoma and ocular hypertension. As an alpha 2 agonist Brimonidine belongs to the same class of drugs as Clonidine; however, its molecular structure is sufficiently different to make it more selective for the alpha 2 receptor than Clonidine. Unlike Clonidine, Brimonidine does not appear to have an effect on the central nervous system and therefore does not cause sedation or systemic hypotension. In addition to their known effect of lowering intraocular pressure, alpha 2 adrenoceptor agonists are neuroprotective. It has, however, been shown that Brimonidine is a very potent vasoconstrictor in the ciliary body thus reducing aqueous humor production. Little is, however, known about potential vasoconstrictor effects of Brimonidine in the posterior pole of the eye. This is of clinical importance, because optic nerve head ischemia appears to contribute to glaucoma pathophysiology. This study is performed to investigate the effects of topical Clonidine vs. topical Brimonidine on choroidal blood flow and intraocular pressure during isometric exercise.

Conditions

• Ocular Physiology
• Regional Blood Flow

Interventions

Type	Name	Description
DRUG	Clonidin
DRUG	Brimonidine

Timeline

• Start date: 2004-02-01
• Completion: 2004-12-01
• First posted: 2006-04-10
• Last updated: 2007-02-12

Locations

1 site across 1 country: Austria